Quarterly ResultMay 13, 2026, 04:37 PM
MaxCyte Q1 Net Loss Narrows to $(4.75)M; Revenue Down 7.1%
AI Summary
MaxCyte reported a net loss of $(4.75) million for Q1 2026, a significant improvement from $(10.26) million in Q1 2025. Total revenue decreased by 7.1% to $9.65 million, primarily due to a 24.6% decline in core revenue, partially offset by a 59.9% increase in non-core revenue. The company also saw a substantial reduction in total operating expenses by 32.7%.
Key Highlights
- Net loss narrowed to $(4.75) million in Q1 2026 from $(10.26) million in Q1 2025.
- Total revenue decreased 7.1% to $9.65 million in Q1 2026 from $10.39 million in Q1 2025.
- Basic and diluted net loss per share improved to $(0.04) from $(0.10) year-over-year.
- Core revenue declined 24.6% to $6.22 million, while non-core revenue grew 59.9% to $3.43 million.
- Total operating expenses decreased 32.7% to $14.27 million from $21.19 million year-over-year.
- Net cash used in operating activities improved to $(8.17) million from $(14.41) million.
- Cash and cash equivalents were $14.56 million as of March 31, 2026.
- Adopted the MaxCyte, Inc. 2026 Inducement Plan in March 2026, reserving 1,000,000 shares.
Price Impact
More from MXCT